Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 in Primary Sjögren's Syndrome
NCT04078386Phase 2Completed
- Sponsor
- RemeGen
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in primary Sjögren's syndrome, sponsored by RemeGen. Started Nov 2019; status: completed.
02
Drugs
telitacicept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04078386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078386.